» Articles » PMID: 37691866

International Expert Consensus on Diagnosis and Treatment of Lung Cancer Complicated by Chronic Obstructive Pulmonary Disease

Abstract

Background: Lung cancer combined by chronic obstructive pulmonary disease (LC-COPD) is a common comorbidity and their interaction with each other poses significant clinical challenges. However, there is a lack of well-established consensus on the diagnosis and treatment of LC-COPD.

Methods: A panel of experts, comprising specialists in oncology, respiratory medicine, radiology, interventional medicine, and thoracic surgery, was convened. The panel was presented with a comprehensive review of the current evidence pertaining to LC-COPD. After thorough discussions, the panel reached a consensus on 17 recommendations with over 70% agreement in voting to enhance the management of LC-COPD and optimize the care of these patients.

Results: The 17 statements focused on pathogenic mechanisms (n=2), general strategies (n=4), and clinical application in COPD (n=2) and lung cancer (n=9) were developed and modified. These statements provide guidance on early screening and treatment selection of LC-COPD, the interplay of lung cancer and COPD on treatment, and considerations during treatment. This consensus also emphasizes patient-centered and personalized treatment in the management of LC-COPD.

Conclusions: The consensus highlights the need for concurrent treatment for both lung cancer and COPD in LC-COPD patients, while being mindful of the mutual influence of the two conditions on treatment and monitoring for adverse reactions.

Citing Articles

Lung Cancer-Epidemiology, Pathogenesis, Treatment and Molecular Aspect (Review of Literature).

Smolarz B, Lukasiewicz H, Samulak D, Piekarska E, Kolacinski R, Romanowicz H Int J Mol Sci. 2025; 26(5).

PMID: 40076671 PMC: 11900952. DOI: 10.3390/ijms26052049.


Proteomic Analysis of Plasma Exosomes Enables the Identification of Lung Cancer in Patients With Chronic Obstructive Pulmonary Disease.

Zhang H, Wu J, Gan J, Wang W, Liu Y, Song T Thorac Cancer. 2025; 16(1):e15517.

PMID: 39778061 PMC: 11717053. DOI: 10.1111/1759-7714.15517.


Integrating genetic and clinical data to predict lung cancer in patients with chronic obstructive pulmonary disease.

Gu Z, Wu Y, Yu F, Sun J, Wang L BMC Pulm Med. 2024; 24(1):618.

PMID: 39696223 PMC: 11656926. DOI: 10.1186/s12890-024-03444-5.


COPD and Immune Checkpoint Inhibitors for Cancer: A Literature Review.

Lycan Jr T, Norton D, Ohar J Int J Chron Obstruct Pulmon Dis. 2024; 19:2689-2703.

PMID: 39677829 PMC: 11639883. DOI: 10.2147/COPD.S490252.


Adaptive medicine, a crucial component of optimized decision making: perspectives from lung cancer management.

Liang W, Zhong R, He J Transl Lung Cancer Res. 2024; 13(6):1185-1189.

PMID: 38973956 PMC: 11225041. DOI: 10.21037/tlcr-24-314.


References
1.
Collins P, Elia M, Stratton R . Nutritional support and functional capacity in chronic obstructive pulmonary disease: a systematic review and meta-analysis. Respirology. 2013; 18(4):616-29. DOI: 10.1111/resp.12070. View

2.
Bolukbas S, Eberlein M, Eckhoff J, Schirren J . Short-term effects of inhalative tiotropium/formoterol/budenoside versus tiotropium/formoterol in patients with newly diagnosed chronic obstructive pulmonary disease requiring surgery for lung cancer: a prospective randomized trial. Eur J Cardiothorac Surg. 2010; 39(6):995-1000. DOI: 10.1016/j.ejcts.2010.09.025. View

3.
Liu S, Reck M, Mansfield A, Mok T, Scherpereel A, Reinmuth N . Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133). J Clin Oncol. 2021; 39(6):619-630. PMC: 8078320. DOI: 10.1200/JCO.20.01055. View

4.
Bongiolatti S, Gonfiotti A, Vokrri E, Borgianni S, Crisci R, Curcio C . Thoracoscopic lobectomy for non-small-cell lung cancer in patients with impaired pulmonary function: analysis from a national database. Interact Cardiovasc Thorac Surg. 2020; 30(6):803-811. DOI: 10.1093/icvts/ivaa044. View

5.
Russo A, Perez D, Gunasekaran M, Scilla K, Lapidus R, Cooper B . Liquid biopsy tracking of lung tumor evolutions over time. Expert Rev Mol Diagn. 2019; 19(12):1099-1108. DOI: 10.1080/14737159.2020.1680287. View